🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "major milestone" in the fight against increasingly resistant strains of the pathogen, according to researchers.

An International Challenge

Cases of gonorrhoea are escalating worldwide, with data suggesting in excess of 82 million infections each year. Particularly high rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely development in the context of growing infection rates, the spread of superbugs and the very limited therapeutic options currently available.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, also known as Nuzolvence, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Experts believe that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the drugmaker GSK, gained clearance in close succession. This medication, which is employed against UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This approval marks a significant shift in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Data and Worldwide Availability

As per results detailed in a major medical journal, the new drug successfully treated the vast majority of cases of the STI. This puts it on an equal footing with the existing first-line therapy, which uses an injection and a pill. The study involved nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in numerous regions with limited resources.

Doctors on the front lines have voiced hope. Access to a one-pill regimen like this is described as a "game-changer" for gonorrhoea control. This is viewed as essential to lessen the impact of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea worldwide.